Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status.

Abstract

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients.

• Authors: Thomas B Casale, Ana Maria Gimenez-Arnau, Jonathan A Bernstein, Michael Holden, Torsten Zuberbier, Marcus Maurer
• Journal: Dermatology and therapy (Dermatol Ther (Heidelb)) Vol. 13 Issue 11 Pg. 2573-2588 (Nov 2023) ISSN: 2193-8210 [Print] Switzerland
• PMID: 37776480 (Publication Type: Journal Article, Review)
• Copyright: © 2023. The Author(s).